First measurement of kaonic helium-3 X-rays

The first observation of the kaonic 3He 3d - 2p transition was made using slow K- mesons stopped in a gaseous 3He target. The kaonic atom X-rays were detected with large-area silicon drift detectors using the timing information of the K+K- pairs of phi-meson decays produced by the DAFNE e+e- collider. The strong interaction shift of the kaonic 3He 2p state was determined to be -2+-2 (stat)+-4 (syst) eV.Comment: Accepted for publication in Phys. Lett.

Isovector soft dipole mode in 6Be

By using the 1H(6Li,6Be)n charge-exchange reaction, continuum states in 6Be were populated up to E_t=16 MeV, E_t being the 6Be energy above its three-body decay threshold. In kinematically complete measurements performed by detecting alpha+p+p coincidences, an E_t spectrum of high statistics was obtained, containing approximately ~5x10^6 events. The spectrum provides detailed correlation information about the well-known 0^+ ground state of 6Be at E_t=1.37 MeV and its 2^+ state at E_t=3.05 MeV. Moreover, a broad structure extending from 4 to 16 MeV was observed. It contains negative parity states populated by Delta L=1 angular momentum transfer without other significant contributions. This structure can be interpreted as a novel phenomenon, i.e. the isovector soft dipole mode associated with the 6Li ground state. The population of this mode in the charge-exchange reaction is a dominant phenomenon for this reaction, being responsible for about 60% of the cross section obtained in the measured energy range.Comment: 8 pages, 7 figure

eta-Nucleus interactions and in-medium properties of N*(1535) in chiral models

The properties of eta-nucleus interaction and their experimental consequences are investigated with eta-nucleus optical potentials obtained by postulating the N*(1535) dominance for eta-N system. The N*(1535) properties in nuclear medium are evaluated by two kinds of chiral effective models based on distinct pictures of N*(1535). We find that these two models provide qualitatively different optical potentials of the eta meson, reflecting the in-medium properties of N*(1535) in these models. In order to compare these models in physical observables, we calculate spectra of (d,3He) reactions for the eta mesic nucleus formation with various kinds of target nuclei. We show that the (d,3He) spectra obtained in these models are significantly different and are expected to be distinguishable in experiments.Comment: 24 pages, 8 figure

Measurements of the strong-interaction widths of the kaonic 3He and 4He 2p levels

The kaonic 3He and 4He X-rays emitted in the 3d-2p transitions were measured in the SIDDHARTA experiment. The widths of the kaonic 3He and 4He 2p states were determined to be Gamma_2p(3He) = 6 \pm 6 (stat.) \pm 7 (syst.) eV, and Gamma_2p(4He) = 14 \pm 8 (stat.) \pm 5 (syst.) eV, respectively. Both results are consistent with the theoretical predictions. The width of kaonic 4He is much smaller than the value of 55 \pm 34 eV determined by the experiments performed in the 70's and 80's, while the width of kaonic 3He was determined for the first time.Comment: Accepted in Phys. Lett.

Antikaon condensation and the metastability of protoneutron stars

We investigate the condensation of $\bar K^0$ meson along with $K^-$ condensation in the neutrino trapped matter with and without hyperons. Calculations are performed in the relativistic mean field models in which both the baryon-baryon and (anti)kaon-baryon interactions are mediated by meson exchange. In the neutrino trapped matter relevant to protoneutron stars, the critical density of $K^-$ condensation is shifted considerably to higher density whereas that of $\bar K^0$ condensation is shifted slightly to higher density with respect to that of the neutrino free case. The onset of $K^-$ condensation always occurs earlier than that of $\bar K^0$ condensation. A significant region of maximum mass protoneutron stars is found to contain $\bar K^0$ condensate for larger values of the antikaon potential. With the appearance of $\bar K^0$ condensation, there is a region of symmetric nuclear matter in the inner core of a protoneutron star. It is found that the maximum mass of a protoneutron star containing $K^-$ and $\bar K^0$ condensate is greater than that of the corresponding neutron star. We revisit the implication of this scenario in the context of the metastability of protoneutron stars and their evolution to low mass black holes.Comment: 26 pages; Revtex; 8 figures include

Production of Slow Protonium in Vacuum

We describe how protonium, the quasi-stable antiproton-proton bound system, has been synthesized following the interaction of antiprotons with the molecular ion H$_2^+$ in a nested Penning trap environment. From a careful analysis of the spatial distributions of antiproton annihilation events in the ATHENA experiment, evidence is presented for protonium production with sub-eV kinetic energies in states around $n$ = 70, with low angular momenta. This work provides a new 2-body system for study using laser spectroscopic techniques.Comment: 9 pages with 5 figures and 1 table. Proceedings of the 4th International Conference on Trapped Charged Particles and Fundamental Physics (TCP 06), published in Hyperfine Interaction

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research